Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2021 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Nov 6, 2020
Slide 1: Investor Presentation Q2FY21 – November 6, 2020
Investor Presentation Q2FY21 – November 6, 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q2FY21 and H1FY21
Key Highlights of Q2FY21 and H1FY21 Recovery in India business, while International business continues its growth momentum • Revenue from Operations grew by 4.4% YoY during the quarter, accompanied by significant expansion in EBITDA margin to 25.4% compared to 20.0% in Q2FY20 • Profit After Tax duri
Slide 4: Key Financial Highlights – Q2FY21 (Consolidated)
Key Financial Highlights – Q2FY21 (Consolidated) All figures in ₹ mn Revenue from Operations India sales YoY: 0.5% 23,628 15,503 15,574 22,640 Q2FY20 Q2FY21 International sales 7,790 6,691 Q2FY20 Q2FY21 Q2FY20 Q2FY21
Slide 5: Key Financial Highlights – Q2FY21 (Consolidated)
Key Financial Highlights – Q2FY21 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 13,597 14,289 6,005 4,526 60.1% 60.5% 20.0% 25.4% Q2FY20 Q2FY21 Q2FY20 Q2FY21 PBT (before Minority Interest) PAT (after Minority Interest) 4,721 5,478 3,709 4,099 Q2FY20 Q2FY21
Slide 6: Key Financial Highlights – H1FY21 (Consolidated)
Key Financial Highlights – H1FY21 (Consolidated) Particulars (₹ mn) H1FY21 H1FY20 YoY growth Revenue from Operations 43,663 41,135 6.1% Gross Profit 26,985 24,974 8.1% Gross Profit margin 61.8% 60.7% EBITDA 11,337 7,171 58.1% EBITDA margin 26.0% 17.4% PBT 10,405 6,199 67.9% PBT margin 23.8% 15.1% PA
Slide 7: India Business
India Business India Business: Q2FY21 Sales of ₹ 15,574 million (0.5% YoY growth) • India sales contributed 66.7% to total sales in Q2FY21 • The Company witnessed recovery in its India sales in Q2FY21 as the Government announced multiple rounds of unlocking • During the quarter, the Company launched
Slide 8: Secondary Sales Performance
Secondary Sales Performance Company’s India business witnessed a recovery in Q2FY21 vs Q1FY21 Alkem’s YoY Alkem’s YoY Alkem’s YoY Therapy segment growth in growth in growth in 6,000 5,620 Q1FY21 Q2FY21 H1FY21 Alkem’s monthly secondary sales (₹ mn) Anti-infectives -22.1% -12.2% -16.4% 5,149 5,000 4,9
Slide 9: US Business
US Business US Business: Q2FY21 Sales of ₹ 6,258 million (18.6% YoY growth) • US sales contributed 26.8% to total sales in Q2FY21 • Growth in US dollar terms was 12% YoY mainly driven by new product launches • In Q2FY21, the Company filed 1 ANDA with the US FDA and received 4 approvals (including 1
Slide 10: US Business
US Business EIR for all the six facilities inspected by the US FDA Facility Capability Last inspection Status post last inspection St. Louis (US) Formulation February 2020 EIR# received in May 2020 Baddi (India) Formulation February 2020 EIR# received in March 2020 Daman (India) Formulation August 2
Slide 11: Other International Business
Other International Business Other International Business: Q2FY21 Sales of ₹ 1,532 million (8.3% YoY growth) • Other International Market sales contributed 6.6% to total sales in Q2FY21 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Chile and Kazakh
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on September 30, 2020 Non-Institution, 20.76% Promoter & Promoter Group, Institution, 62.43% 16.81% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other
Slide 13: Thank You
Thank You For further information or queries please contact Gagan Borana Investor Relations – Alkem Laboratories Ltd. Tel: +91 22 3982 9960 E-mail: [email protected]